Full Text
The Full Text of this article is available as a PDF (87.0 KB).
References
- 1.Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med. 2000;343:1520–28. doi: 10.1056/NEJM200011233432103. [DOI] [PubMed] [Google Scholar]
- 2.Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med. 2005;352:1081–91. doi: 10.1056/NEJMoa050493. [DOI] [PubMed] [Google Scholar]
- 3.Nussmeier NA, Whelton AA, Brown MT, Langford RM, et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med. 2005;352:1081–91. doi: 10.1056/NEJMoa050330. [DOI] [PubMed] [Google Scholar]
- 4.FDA Talk Paper “Bextra label updated with boxed warning concerning severe skin reactions and warning regarding cardiovascular risk.” Available at: http://www.fda. gov/bbs/topics/ANSWERS/2004/ANS01331.html.
- 5.Drazen JM. COX-2 inhibitors—A lesson in unexpected problems. N Engl J Med. 2005;352:1131–1131. doi: 10.1056/NEJMe058038. [DOI] [PubMed] [Google Scholar]
- 6.Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA. 2001;286:954–959. doi: 10.1001/jama.286.8.954. [DOI] [PubMed] [Google Scholar]
- 7.Psaty BM, Furberg CD. COX-2 Inhibitors—Lessons in Drug Safety. N Eng J Med. 2005;352:1133–1133. doi: 10.1056/NEJMe058042. [DOI] [PubMed] [Google Scholar]